151 related articles for article (PubMed ID: 32910788)
1. Efficacy of elbasvir/grazoprevir therapy in HCV genotype-1 with or without HIV infection: role of HCV core antigen monitoring and improvement of liver stiffness and steatosis.
Chayanupatkul M; Chittmittraprap S; Pratedrat P; Chuaypen N; Avihingsanon A; Tangkijvanich P
Antivir Ther; 2020; 25(6):305-314. PubMed ID: 32910788
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study.
Brown A; Hézode C; Zuckerman E; Foster GR; Zekry A; Roberts SK; Lahser F; Durkan C; Badshah C; Zhang B; Robertson M; Wahl J; Barr E; Haber B;
J Viral Hepat; 2018 May; 25(5):457-464. PubMed ID: 29152828
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.
Gane E; Nahass R; Luketic V; Asante-Appiah E; Hwang P; Robertson M; Wahl J; Barr E; Haber B
J Viral Hepat; 2017 Oct; 24(10):895-899. PubMed ID: 28470815
[TBL] [Abstract][Full Text] [Related]
4. Impact of recent drug use on the efficacy of elbasvir/grazoprevir for HCV-infected people on opioid agonist therapy.
Macías J; Téllez F; de Los Santos I; Morano LE; Merino D; Granados R; Vera-Mendez F; González-Serna A; Campo-Moneo E; García-Fraile L; García F; Real LM; Pineda JA;
J Viral Hepat; 2021 Jun; 28(6):878-886. PubMed ID: 33721377
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Sulkowski M; Hezode C; Gerstoft J; Vierling JM; Mallolas J; Pol S; Kugelmas M; Murillo A; Weis N; Nahass R; Shibolet O; Serfaty L; Bourliere M; DeJesus E; Zuckerman E; Dutko F; Shaughnessy M; Hwang P; Howe AY; Wahl J; Robertson M; Barr E; Haber B
Lancet; 2015 Mar; 385(9973):1087-97. PubMed ID: 25467560
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
Kramer JR; Puenpatom A; Erickson KF; Cao Y; Smith D; El-Serag HB; Kanwal F
J Viral Hepat; 2018 Nov; 25(11):1270-1279. PubMed ID: 29851265
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population.
Choi DT; Puenpatom A; Yu X; Erickson KF; Kanwal F; El-Serag HB; Kramer JR
Antiviral Res; 2020 Feb; 174():104698. PubMed ID: 31862503
[TBL] [Abstract][Full Text] [Related]
8. An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
Lee YJ; Heo J; Kim DY; Chung WJ; Tak WY; Kim YJ; Paik SW; Sim E; Kulasingam S; Talwani R; Haber B; Hwang P
Clin Mol Hepatol; 2019 Dec; 25(4):400-407. PubMed ID: 31132846
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Jacobson IM; Lawitz E; Kwo PY; Hézode C; Peng CY; Howe AYM; Hwang P; Wahl J; Robertson M; Barr E; Haber BA
Gastroenterology; 2017 May; 152(6):1372-1382.e2. PubMed ID: 28193518
[TBL] [Abstract][Full Text] [Related]
10. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.
Kumada H; Suzuki Y; Karino Y; Chayama K; Kawada N; Okanoue T; Itoh Y; Mochida S; Toyoda H; Yoshiji H; Takaki S; Yatsuzuka N; Yodoya E; Iwasa T; Fujimoto G; Robertson MN; Black S; Caro L; Wahl J
J Gastroenterol; 2017 Apr; 52(4):520-533. PubMed ID: 27873094
[TBL] [Abstract][Full Text] [Related]
11. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study.
Calvaruso V; Petta S; Ferraro D; La Mantia C; Gibilaro G; Reina G; Di Maio VC; Licata A; Ceccherini-Silberstein F; Di Marco V; Craxì A
Dig Liver Dis; 2022 Aug; 54(8):1117-1121. PubMed ID: 34593348
[TBL] [Abstract][Full Text] [Related]
13. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.
Lawitz E; Poordad F; Gutierrez JA; Wells JT; Landaverde CE; Evans B; Howe A; Huang HC; Li JJ; Hwang P; Dutko FJ; Robertson M; Wahl J; Barr E; Haber B
Hepatology; 2017 Feb; 65(2):439-450. PubMed ID: 27770561
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States.
Elbasha EH; Robertson MN; Nwankwo C
Aliment Pharmacol Ther; 2017 Feb; 45(3):455-467. PubMed ID: 27910116
[TBL] [Abstract][Full Text] [Related]
15. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.
Liu CH; Peng CY; Fang YJ; Kao WY; Yang SS; Lin CK; Lai HC; Su WP; Fang SU; Chang CC; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
Sci Rep; 2020 Jun; 10(1):9180. PubMed ID: 32513953
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study.
Jang ES; Kim KA; Kim YS; Kim IH; Lee BS; Lee YJ; Chung WJ; Jeong SH
Korean J Intern Med; 2021 Mar; 36(Suppl 1):S1-S8. PubMed ID: 32539296
[TBL] [Abstract][Full Text] [Related]
17. Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam.
Nwankwo C; Corman SL; Elbasha EH
J Infect Public Health; 2019; 12(4):502-508. PubMed ID: 30711348
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hepatitis C virus infection in people with opioid use disorder: a real-world study of elbasvir/grazoprevir in a US Department of Veterans Affairs population.
Kramer JR; Puenpatom A; Cao Y; Yu X; El-Serag HB; Kanwal F
Am J Drug Alcohol Abuse; 2022 Jul; 48(4):445-453. PubMed ID: 35077656
[No Abstract] [Full Text] [Related]
19. The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial.
AlEid A; Al Balkhi A; Qutub A; Abbarh S; AlLehibi A; Almtawa A; Al Otaibi N; AlGhamdi A; AlGhamdi A; Alamr A; Ahmad S; Al Sayari K; Al Ibrahim B; AlKhathlan A
Saudi J Gastroenterol; 2022; 28(3):225-232. PubMed ID: 35142658
[TBL] [Abstract][Full Text] [Related]
20. Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Toyoda H; Atsukawa M; Takaguchi K; Senoh T; Michitaka K; Hiraoka A; Fujioka S; Kondo C; Okubo T; Uojima H; Tada T; Yoneyama H; Watanabe T; Asano T; Ishikawa T; Tamai H; Abe H; Kato K; Tsuji K; Ogawa C; Shimada N; Iio E; Deguchi A; Itobayashi E; Mikami S; Moriya A; Okubo H; Tani J; Tsubota A; Tanaka Y; Masaki T; Iwakiri K; Kumada T
J Gastroenterol; 2018 Dec; 53(12):1276-1284. PubMed ID: 29740665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
